Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes

Clinical Biochemistry

Volumn 42, Issue 1-2, 2009, Pages 17-21

  Wu, Xiaopan ^a   Niu, Nifang ^a   Brismar, Kerstin ^b   Zhu, Xilin ^a   Wang, Xin ^a   Efendic, Suad ^b   Du, Te ^a   Liu, Yang ^a   Gu, Harvest F ^b   Liu, Ying ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apolipoprotein M; Association study; Promoter activity; Single nucleotide polymorphism; Type 1 diabetes

Indexed keywords

APOLIPOPROTEIN M; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN; LUCIFERASE;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CHINA; CHINESE; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEPATOMA CELL; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN;

APOLIPOPROTEINS; ASIAN CONTINENTAL ANCESTRY GROUP; CELL LINE; CHINA; DIABETES MELLITUS, TYPE 1; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 57649171693     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.10.008     Document Type: Article

References (20)

1. Abel M.M.A., and Krokowski M. Pathophysiology of immune-mediated (type 1) diabetes mellitus: potential for immunotherapy. BioDrugs 15 (2001) 291-301
2. Sparre T., Bergholdt R., Nerup J., and Pociot F. Application of genomics and proteomics in Type 1 diabetes pathogenesis research. Expert. Rev. Mol. Diagn. 3 (2003) 743-757
3. Karvonen M., Viik-Kajander M., Moltchanova E., Libman I., LaPorte R., and Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabet. Care 23 (2000) 1516-1526
4. Aribi M. Candidate genes implicated in type 1 diabetes susceptibility. Curr. Diabetes Rev. 4 (2008) 110-121
5. Pugliese A., and Eisenbarth G.S. Type 1 diabetes mellitus of man: genetic susceptibility and resistance. Adv. Exp. Med. Biol. 552 (2004) 170-203
6. Xu N., and Dahlback B. A novel human apolipoprotein (apoM). J. Biol. Chem. 274 (1999) 31286-31290
7. Duan J., Dahlback B., and Villoutreix B.O. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett. 499 (2001) 127-132
8. Wolfrum C., Poy M.N., and Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat. Med. 11 (2005) 418-422
9. Balakrishnan S., Colling C., Burkman T., Erickson J., Lyden E., Maheshwari H., et al. Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation. Transplantation 74 (2002) 974-977
10. Klein R.L., McHenry M.B., Lok K.H., Hunter S.J., Le N.A., Jenkins A.J., et al. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism 53 (2004) 1296-1304
11. Xu N., Ahren B., Jiang J., and Nilsson-Ehle P. Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. Biochim. Biophys. Acta 1761 (2006) 256-260
12. Xu N., Hurtig M., Zhang X.Y., Ye Q., and Nilsson-Ehle P. Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells. Biochim. Biophys. Acta 1683 (2004) 33-37
13. Huang X.S., Zhao S.P., Hu M., and Luo Y.P. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med. Hypotheses 69 (2007) 136-140
14. Niu N., Zhu X., Liu Y., Du T., Wang X., Chen D., et al. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. Diabetes. Metab. Res. Rev. 23 (2007) 21-25
15. Shi Y.Y., and He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15 (2005) 97-98
16. Xu N., Nilsson-Ehle P., and Ahren B. Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: partial reversal by insulin. Biochem. Biophys. Res. Commun. 342 (2006) 1174-1177
17. Zhang X., Jiang B., Luo G., Nilsson-Ehle P., and Xu N. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochim. Biophys. Acta 1771 (2007) 879-882
18. Richter S., Shih D.Q., Pearson E.R., Wolfrum C., Fajans S.S., Hattersley A.T., et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 52 (2003) 2989-2995
19. Xu N., Nilsson-Ehle P., and Ahren B. Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. J. Nutr. Biochem. 15 (2004) 579-582
20. Jiao G.Q., Yuan Z.X., Xue Y.S., Yang C.J., Lu C.B., Lu Z.Q., et al. A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese. Clin. Biochem. 40 (2007) 1108-1112